La Fraise has secured a €3.2 million investment to enhance its AI-driven platform aimed at reducing treatment abandonment in dental care.

Target Information

La Fraise is an innovative startup founded in 2025 that specializes in enhancing dental practice management through the use of artificial intelligence. The company has developed AI agents designed to support dental teams by automating both repetitive and complex tasks. This revolutionary platform aims to alleviate common issues faced by dental professionals, such as managing treatment plans and navigating insurance communications, ultimately improving patient care.

Founded by four former Doctolib alumni — Cédric Turquem, Matthieu Kern, Victor Schubert, and Florian Duchêne — La Fraise benefits from the extensive experience of its team, which has over eight years of expertise in healthcare innovation. In conjunction with Arnaud Assous, a successful serial entrepreneur, they provide La Fraise with a solid foundation for growth and transformation in the dental care sector.

Industry Overview

The dental care industry in France is witnessing significant challenges, with nearly one-third of individuals avoiding essential dental treatment primarily due to a lack of information regarding medical, f

View Source

Similar Deals

GO Capital and Critical Path Ventures Alkion BioInnovations

2025

Seed Stage Biotechnology & Medical Research (NEC) France
Critical Path Ventures Sonomind

2025

Seed Stage Bio Medical Devices France
GO CAPITAL, DEMETER Sirius Neosight

2025

Seed Stage Bio Diagnostics & Testing France
Mutuelles Impact, Newfund Diagnoly

2025

Seed Stage Bio Diagnostics & Testing France

20VC, Kima Ventures

invested in

La Fraise

in 2025

in a Seed Stage deal

Disclosed details

Transaction Size: $3M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert